Lyka Labs

Which are the latest news on Lyka Labs?

How big is Lyka Labs?

As of 10th June, Lyka Labs Ltd has a market capitalization of 270.00 Cr and reported net sales of 128.45 Cr with a net loss of 10.04 Cr over the latest four quarters.

As of 10th June, <BR><BR>Market Cap: Lyka Labs Ltd has a market capitalization of 270.00 Cr, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 128.45 Cr, while the sum of Net Profit for the same period reflects a loss of 10.04 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period for the balance sheet is March 2025, with Shareholder's Funds amounting to 103.55 Cr and Total Assets valued at 176.21 Cr.

Why is Lyka Labs Ltd falling/rising?

As of 10-Jun, Lyka Labs Ltd's stock price is rising to 72.45, reflecting a 3.78% increase. This surge is driven by a significant weekly gain of 26.22%, strong investor interest, and consistent performance above shorter-term moving averages, despite being below the 200-day average.

As of 10-Jun, Lyka Labs Ltd's stock price is rising, currently at 72.45, reflecting an increase of 2.64 or 3.78%. This upward movement can be attributed to several factors. Over the past week, the stock has shown a significant gain of 26.22%, while the benchmark Sensex has decreased by 0.49%, indicating strong relative performance. Additionally, in the last two days, the stock has consistently gained, resulting in a total return of 14.15% during this period.<BR><BR>Today, the stock opened with a notable gap up of 7.36% and reached an intraday high of Rs 76.79, which is a 10% increase. The stock's performance today has outperformed its sector by 4.24%. Furthermore, there has been a marked increase in investor participation, with delivery volume rising by 114.63% compared to the 5-day average, suggesting heightened interest and confidence among investors. <BR><BR>While the stock is currently above its 5-day, 20-day, 50-day, and 100-day moving averages, it remains below the 200-day moving average, indicating a potential upward trend in the short term despite its longer-term performance challenges. Overall, these factors contribute to the rising stock price of Lyka Labs Ltd.

What does Lyka Labs do?

Lyka Labs Ltd is a micro-cap company in the Pharmaceuticals & Biotechnology sector, focusing on manufacturing formulations, bulk drugs, and healthcare products. As of March 2026, it reported net sales of 28 Cr and a net loss of 8 Cr, with a market cap of INR 270 Cr.

Overview: <BR>Lyka Labs Ltd operates in the Pharmaceuticals & Biotechnology industry as a micro-cap company, focusing on the manufacturing of formulations, bulk drugs, and a range of healthcare products.<BR><BR>History: <BR>Lyka Labs was incorporated in April 1983, initially manufacturing formulations and later amalgamating with Lyphin Chemicals Pvt Ltd. Over the years, it diversified into marketing medical and diagnostic equipment. The latest quarterly results reported net sales and profit for March 2026.<BR><BR>Financial Snapshot: <BR>Net Sales: 28 Cr (Quarterly Results - Mar 2026) <BR>Net Profit: -8 Cr (Quarterly Results - Mar 2026) <BR>Market Cap: INR 270 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: N/A <BR>Industry P/E: 34 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.51 <BR>Return on Equity: -10.87% <BR>Price to Book: 2.70<BR><BR>Contact Details: <BR>Address: 4801/B & 4802/A, GIDC Industrial Estate Ankleshwar Gujarat : 393002 <BR>Tel: 91-02646-221422/220549 <BR>Email: companysecretary@lykalabs.com <BR>Website: http://www.lykalabs.com

Are Lyka Labs Ltd latest results good or bad?

Lyka Labs Ltd's latest Q4 FY26 results are concerning, showing a net loss of ₹7.61 crores and a 16.15% revenue decline, marking the lowest quarterly revenue in seven quarters. Analysts have downgraded the company's financial outlook to "Negative," indicating significant operational challenges and a bleak future without a turnaround strategy.

Lyka Labs Ltd's latest results for Q4 FY26 are concerning and indicate a significant deterioration in financial performance. The company reported a net loss of ₹7.61 crores, which marks a drastic decline of 529.94% year-on-year. Revenue also fell to ₹28.03 crores, down 16.15% compared to the same quarter last year and representing the lowest quarterly revenue in the past seven quarters.<BR><BR>The operating margin has turned deeply negative at -23.05%, the worst level recorded, and the profit after tax (PAT) margin is at -28.79%, highlighting severe operational inefficiencies. The company's financial trend has been downgraded to "Negative" by analysts, reflecting growing concerns about its operational viability.<BR><BR>Additionally, the stock has underperformed significantly, declining 47.08% over the past year, which is starkly worse than both the Sensex and the pharmaceuticals sector. Overall, these results suggest that Lyka Labs is facing a critical operational crisis, and the outlook appears bleak without a clear turnaround strategy.

Should I buy, sell or hold Lyka Labs Ltd?

When is the next results date for Lyka Labs Ltd?

The next results date for Lyka Labs Ltd is 25 May 2026.

The next results date for Lyka Labs Ltd is scheduled for 25 May 2026.

Is Lyka Labs overvalued or undervalued?

As of November 13, 2025, Lyka Labs is considered overvalued with a high PE ratio of 156.53 and a significant decline in performance, contrasting with its peers, which have more attractive valuations and growth expectations.

As of 13 November 2025, Lyka Labs has moved from an attractive to a fair valuation grade, indicating a shift in its perceived investment quality. The company is currently considered overvalued based on its high PE ratio of 156.53, an EV to EBIT of 119.79, and a Price to Book Value of 3.16. These ratios suggest that the stock is trading at a premium compared to its earnings and book value.<BR><BR>In comparison to its peers, Lyka Labs' PE ratio significantly exceeds that of Cipla, which stands at 22.65, and Dr. Reddy's Labs at 17.86, both of which are classified as attractive. Additionally, while Lyka Labs has a PEG ratio of 0.00, indicating no growth expectations, its peers like Sun Pharma and Divi's Lab are categorized as expensive with PEG ratios of 11.96 and 1.99, respectively. The recent performance of Lyka Labs shows a substantial decline, with a year-to-date return of -43.61%, contrasting sharply with the Sensex's positive return of 8.11% during the same period, further reinforcing the overvaluation narrative.

How has been the historical performance of Lyka Labs?

Lyka Labs has shown fluctuating historical performance, with net sales increasing from 93.07 Cr in Mar'23 to 138.50 Cr in Mar'25, while total operating income peaked at 194.08 Cr in Mar'22 before declining. Despite rising costs and low cash flow, the company improved profitability, achieving a profit after tax of 7.93 Cr in Mar'25, recovering from previous losses.

Answer:<BR>The historical performance of Lyka Labs shows a fluctuating trajectory over the years, with notable improvements in recent periods.<BR><BR>Breakdown:<BR>Lyka Labs' net sales increased from 93.07 Cr in Mar'23 to 138.50 Cr in Mar'25, reflecting a positive growth trend. However, the total operating income peaked at 194.08 Cr in Mar'22 before declining to 138.50 Cr in Mar'25. The total expenditure, excluding depreciation, rose from 76.23 Cr in Mar'23 to 120.56 Cr in Mar'25, indicating rising costs. Operating profit (PBDIT) showed volatility, with a high of 103.24 Cr in Mar'22, dropping to 20.17 Cr in Mar'25. Profit before tax improved to 11.12 Cr in Mar'25 from a loss of 13.23 Cr in Mar'23, while profit after tax also turned positive at 7.93 Cr in Mar'25, recovering from losses in previous years. The company's total assets increased to 176.21 Cr in Mar'25, up from 151.52 Cr in Mar'23, and total liabilities also rose to 176.21 Cr in Mar'25. Cash flow from operating activities remained low at 1.00 Cr in Mar'25, with a net cash outflow of 4.00 Cr. Overall, while Lyka Labs has shown signs of recovery in profitability and sales, it continues to face challenges with rising costs and cash flow management.

What is the technical trend for Lyka Labs?

As of June 2, 2025, Lyka Labs shows a mildly bearish trend, supported by daily moving averages and a bearish monthly MACD, despite mixed signals from the weekly MACD and Bollinger Bands.

As of 2 June 2025, the technical trend for Lyka Labs has changed from sideways to mildly bearish. The weekly MACD is mildly bullish, but the monthly MACD is mildly bearish, indicating mixed signals. The daily moving averages are also mildly bearish, reinforcing the bearish sentiment. Bollinger Bands on the monthly chart show a bearish trend, while both the KST and Dow Theory indicate no clear trend on a monthly basis. Overall, the current stance is mildly bearish, with the daily moving averages and monthly MACD being key indicators driving this outlook.

Who are the top shareholders of the Lyka Labs?

The top shareholders of Lyka Labs primarily include promoters, with Ipca Laboratories Limited as the largest shareholder at 40.98%. Other notable shareholders are Thermo Capital Private Limited (1.55%) and individual investors (31.18%), along with minimal stakes from mutual funds and foreign institutional investors.

The top shareholders of Lyka Labs include several key players. The majority of the shares are held by promoters, with Ipca Laboratories Limited being the largest individual shareholder, holding 40.98%. Other notable shareholders include Thermo Capital Private Limited, which holds 1.55%, and individual investors collectively owning 31.18%. Additionally, there are four mutual fund schemes with a very small stake of 0.01% and five foreign institutional investors (FIIs) holding 0.23%. Overall, the promoter group plays a significant role in the ownership structure of Lyka Labs.

Who are in the management team of Lyka Labs?

As of March 2023, the management team of Lyka Labs includes Kunal Narendra Gandhi (Chairman & MD & CEO), Yogesh B Shah (Executive Director & CFO), and several independent and non-executive directors, overseeing the company's operations and strategy.

As of March 2023, the management team of Lyka Labs includes the following members:<BR><BR>1. Kunal Narendra Gandhi - Chairman & MD & CEO<BR>2. Sandeep P Parikh - Non-Executive & Independent Director<BR>3. Yogesh B Shah - Executive Director & CFO<BR>4. Dhara P. Shah - Non-Executive & Independent Director<BR>5. Kishore P Shah - Company Secretary & Compliance Officer<BR>6. Babulal Jain - Independent Director<BR>7. Prashant Godha - Director<BR>8. Shashil Mendonsa - Director<BR><BR>This team is responsible for overseeing the company's operations and strategic direction.

Has Lyka Labs declared dividend?

No Dividend History Available

Who are the peers of the Lyka Labs?

Lyka Labs' peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Brooks Lab, Everest Organics, SMS Lifesciences, and Zenotech Lab. Lyka Labs has average growth and below average capital structure, with a 1-year return of 11.65%, higher than Cipla's but lower than Everest Organics' 252.60%.

Peers: The peers of Lyka Labs are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Brooks Lab., Everest Organics, SMS Lifesciences, and Zenotech Lab.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, and Lyka Labs, while Average management risk is found at Everest Organics, SMS Lifesciences, and Zenotech Lab. Growth is excellent at Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Average growth is noted at Lyka Labs, and Below Average growth is seen at Divi's Lab., Torrent Pharma, Brooks Lab., Everest Organics, SMS Lifesciences, and Zenotech Lab. Capital structure is excellent at Sun Pharma.Inds., Divi's Lab., Cipla, and Dr Reddy's Labs, while Below Average capital structure is noted at Lyka Labs, Brooks Lab., Everest Organics, and the rest.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Everest Organics at 252.60%, while the peer with the lowest is Cipla at 0.84%. Lyka Labs has a 1-year return of 11.65%, which is higher than Cipla's but lower than Everest Organics'. Additionally, peers with negative six-month returns include Lyka Labs and Zenotech Lab.